John F. Bedard
Corporate Officer/Principal bei Drug Information Association
Profil
Mr. John F.
Bedard is Independent Director at Synvista Therapeutics, Inc., a Member at Drug Information Association, and a Member at New York Academy of Sciences.
He is on the Board of Directors at Synvista Therapeutics, Inc.
Mr. Bedard was previously employed as a Member by American Association for the Advancement of Science and Vice President-FDA Liaison & Global Strategy by Bristol-Myers Squibb Co. He also served on the board at EpiCept Corp.
and Maxim Pharmaceuticals, Inc.
He received his undergraduate degree from Rutgers University (New Jersey) and a graduate degree from St. Joseph's University.
Aktive Positionen von John F. Bedard
| Unternehmen | Position | Beginn |
|---|---|---|
Drug Information Association
 Drug Information Association Miscellaneous Commercial ServicesCommercial Services The Drug Information Association is a non-profit multidisciplinary association that operates to promote health and well-being. The non-profit company is based in Horsham, PA. Marwan Fathallah has been the CEO of the company since 2023. | Corporate Officer/Principal | - |
New York Academy of Sciences
 New York Academy of Sciences Miscellaneous Commercial ServicesCommercial Services New York Academy of Sciences is an independent, not-for-profit organization, which engages in the advancement of scientific research, education, and policy. The company was founded in 1817 and is headquartered in New York, NY. | Corporate Officer/Principal | - |
Ehemalige bekannte Positionen von John F. Bedard
| Unternehmen | Position | Ende |
|---|---|---|
EpiCept Corp.
 EpiCept Corp. Pharmaceuticals: MajorHealth Technology EpiCept Corp. is a pharmaceutical company, which focuses on the clinical development and commercialization of pharmaceutical products for the treatment of cancer and pain. The company focuses on analgesics targeting peripheral nerve receptors and cancer therapies. Its lead product Ceplene, is used concomitantly with low-dose interleukin-2, is intended as remission maintenance therapy in the treatment of acute myeloid leukemia for adult patients. The company's other oncology compounds include AmiKet, a late-stage pain product candidate for the treatment of peripheral neuropathies, and two other oncology compounds in clinical development, that that were discovered using in-house technology and have been shown to act as vascular disruption agents in solid tumors. EpiCept was founded in March 1993 and is headquartered in Tarrytown, NY. | Direktor/Vorstandsmitglied | 03.02.2009 |
| Maxim Pharmaceuticals, Inc. | Direktor/Vorstandsmitglied | 06.01.2006 |
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | 01.01.2002 |
American Association for the Advancement of Science
 American Association for the Advancement of Science Miscellaneous Commercial ServicesCommercial Services The American Association for the Advancement of Science provides science related journal, program, and education services. The firm also promotes the responsible use of science in public policy. The company was founded in 1848 and is headquartered in Washington, DC. | Corporate Officer/Principal | - |
| SYNVISTA THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | - |
Ausbildung von John F. Bedard
| Rutgers State University of New Jersey | Undergraduate Degree |
| St. Joseph's University | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| SYNVISTA THERAPEUTICS, INC. | Health Technology |
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| Private Unternehmen | 5 |
|---|---|
| Maxim Pharmaceuticals, Inc. | Health Technology |
EpiCept Corp.
EpiCept Corp. Pharmaceuticals: MajorHealth Technology EpiCept Corp. is a pharmaceutical company, which focuses on the clinical development and commercialization of pharmaceutical products for the treatment of cancer and pain. The company focuses on analgesics targeting peripheral nerve receptors and cancer therapies. Its lead product Ceplene, is used concomitantly with low-dose interleukin-2, is intended as remission maintenance therapy in the treatment of acute myeloid leukemia for adult patients. The company's other oncology compounds include AmiKet, a late-stage pain product candidate for the treatment of peripheral neuropathies, and two other oncology compounds in clinical development, that that were discovered using in-house technology and have been shown to act as vascular disruption agents in solid tumors. EpiCept was founded in March 1993 and is headquartered in Tarrytown, NY. | Health Technology |
Drug Information Association
Drug Information Association Miscellaneous Commercial ServicesCommercial Services The Drug Information Association is a non-profit multidisciplinary association that operates to promote health and well-being. The non-profit company is based in Horsham, PA. Marwan Fathallah has been the CEO of the company since 2023. | Commercial Services |
New York Academy of Sciences
New York Academy of Sciences Miscellaneous Commercial ServicesCommercial Services New York Academy of Sciences is an independent, not-for-profit organization, which engages in the advancement of scientific research, education, and policy. The company was founded in 1817 and is headquartered in New York, NY. | Commercial Services |
American Association for the Advancement of Science
American Association for the Advancement of Science Miscellaneous Commercial ServicesCommercial Services The American Association for the Advancement of Science provides science related journal, program, and education services. The firm also promotes the responsible use of science in public policy. The company was founded in 1848 and is headquartered in Washington, DC. | Commercial Services |
